Different fusion genes of BCR-ABL1 are all leukemogenic for acute lymphoblastic leukemia or chronic myeloid leukemia (CML). According to results published in Leukemia, the particular transcripts present in patients with CML are correlated with sex and age and are not constant worldwide. This study systematically assessed the frequency of these leukemogenic fusion genes in patients…
The FDA has approved Venclexta in combination with Gazyva for the treatment of patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
The FDA has expanded the indication for Tibsovo to include treatment of newly diagnosed acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Bruce Levine, PhD, explains why targeting multiple antigens simultaneously may be the most promising approach for adoptive cell therapies such as CAR-T.
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Patients with rapid early response demonstrated increased event-free and overall survival when receiving augmented postinduction intensification regimens.
With advances in cancer research and treatments, patients with acute lymphoblastic leukemia (ALL) can enjoy longer lives and treatment can continue long after initial hospital admission and into the outpatient setting.1,2 Parents of children with leukemia often find themselves serving as direct caregivers for their children, an important role that may require them to receive…
Specific cytogenetic abnormalities are associated with patient outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and may have prognostic value, according to a study published in Leukemia. A multinational research team conducted a retrospective analysis of clinical outcomes of patients with AML undergoing allogeneic HSCT while taking into account recurring…
CAR T therapy has emerged in recent years as a feasible treatment for patients with chronic lymphocytic leukemia, but there are still many unanswered questions.
The identification of 8 new subtypes of B progenitor acute lymphoblastic leukemia may guide the diagnosis and development of more effective targeted therapies.
Venetoclax and hypomethylating agents, which both demonstrate single agent activity in acute myeloid leukemia, appear to be more effective when used together.
The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.
